- 2012 ESMO General Assembly
- 2084: A play in three acts
- A paradigm shift in early drug development: Individualizing to more patient benefit
- A patient with EGFR mutation who progresses to reversible EGFR TKI: What should we do?
- Basic Science and Translational Research I
- Basic Science and Translational Research II
- Biologically based treatment in head and neck squamous cell carcinoma
- Biomarkers in breast and colorectal cancer
- Biomarkers in lung cancer
- Breast cancer, early stage
- Breast cancer, early stage
- Breast cancer, locally advanced and metastatic
- Breast cancer, metastatic
- Bulky lymphoma of the mediastinum
- CNS tumors
- CNS tumors
- Cancer pain management: First presentation of the findings of the International Collaborative Project
- Can neo-adjuvant breast cancer data be used to accelerate drug approval?
- Challenges for patients with rare cancers
- Challenges in doctor-patient communications
- Clinical approaches to germline genetic testing in oncology
- Clinical practice guidelines in rare solid cancers: A comparison across the two sides of the Atlantic
- Congress preview
- Decision making & management of glioma: Practical considerations
- Decision making & management of glioma: Practical considerations - Repetition
- Deep DNA sequencing of tumor: ready for prime-time or not?
- Developmental therapeutics
- Developmental therapeutics
- Developments in early NSCLC
- Developments in early NSCLC - Repetition
- Diagnosis and management issues in colorectal cancer
- Diagnosis and management issues in colorectal cancer - Repetition
- Diagnosis and management issues in lymphoma
- Diagnosis and management issues in lymphoma - Repetition
- Diagnosis and management issues in melanoma
- Diagnosis and management issues in melanoma - Repetition
- Diagnosis and management issues in ovarian cancer
- Diagnosis and management issues in ovarian cancer- Repitition
- Diagnosis and management issues in pancreatic cancer
- Diagnosis and management issues in pancreatic cancer - Repetition
- EGFR inhibitors are the best choice for the first line treatment of EGFR mutated lung adenocarcinoma patients
- ERC: Funding opportunities for scientists
- ESMO-ASCO Joint symposium: Genomics in breast cancer: Opening new doors
- ESMO-CSCO Joint symposium: Building the clinical trials of the future
- ESMO-EACR Joint symposium: Targeted therapies: Promises, successes and failures
- ESMO-EANM-ESR Joint symposium: Imaging biomarkers in the era of targeted therapies
- ESMO-ESP Joint Symposium: Molecular diagnostics for personalized cancer treatment
- ESMO-ESTRO Joint symposium: Innovative approaches to the treatment of brain metastases
- ESMO-JSMO Joint symposium: Recent advances in the treatment of GI tract and liver cancer in the EU and Japan
- ESMO-MASCC Joint symposium: Integration between medical oncology and supportive care: Two sides of the same coin
- ESMO Clinical Practice Guidelines 1
- ESMO Clinical Practice Guidelines 2
- ESMO DCTF-AORTIC-SLACOM-UICC-WHO Joint Symposium: Independent and publicly funded research: a new global model
- ESMO Examination
- Emerging diagnostic and therapeutic targets in gynecological cancers: From science to clinical practice
- Evidence-based answers to critical questions on cancer screening and prevention
- Excellence in care and chemotherapy: Goals and challenges for the oncology team
- Extranodal lymphomas
- Fellowships in Europe: Educational opportunities for European Young Medical Oncologists. An ESMO-AERIO-AIOM-HESMO-SEOM YO session
- From biology to treatment in advanced pancreatic and gastroesophageal cancer
- Gastrointestinal tumors, colorectal
- Gastrointestinal tumors, non-colorectal
- Gastrointestinal tumors, non-colorectal
- Gatrointestinal tumors, colorectal
- Genitourinary tumors, bladder and testicular cancer
- Genitourinary tumors, non-prostate (renal cancer)
- Genitourinary tumors, prostate
- Genitourinary tumors, prostate I
- Genitourinary tumors, prostate II
- Genitourinary tumors, renal cancer
- Geriatric oncology: Issues that also relate to cancer in younger patients
- Getting biology into treatment
- Gynecological cancer
- Gynecological cancers
- HPV biology and implications in gynecological malignancies
- Head and neck cancer
- Head and neck cancer
- Hematological malignancies
- Hematological malignancies
- Hepatocellular carcinoma (HCC)
- Hot topics in early stage NSCLC
- How can medical oncologists deal with the new wave of genetic information about their patients?
- How soon will colorectal patients management be driven by molecular factors?
- How to integrate new drugs in the current therapeutic landscape of metastatic triple negative breast cancer
- How to make an impact on clinical research in the early stages of your career
- How to optimize the sequence of multidisciplinary treatment in patients with non resectable liver metastases and pancreatic neuroendocrine primary
- How to plan and conduct a successful research fellowship abroad
- How to select amongst available options for the treatment of advanced RCC
- How to select amongst available options for the treatment of advanced RCC - Repetition
- How to select amongst available options for the treatment of multiple myeloma
- How to select amongst available options for the treatment of multiple myeloma- Repetition
- How to write a good review article
- Industry Satellite: Amgen: Achieving new standards in bone metastases treatment INVITE
- Industry Satellite: Amgen: Personalising medicine for GI cancers INVITE
- Industry Satellite: Astra Zeneca: Biomarker-directed treatment of advanced non-small cell lung cancer
- Industry Satellite: BMS: Navigating the evolving landscape of advanced melanoma
- Industry Satellite: Baxter: European consensus-based cancer cachexia framework: evidence and practices
- Industry Satellite: Bayer: Rapid progress in CRPC: How new agents should change our thinking
- Industry Satellite: Bayer: Translating advances in molecular oncology to the clinic for the treatment of mCRC and GIST
- Industry Satellite: Boehringer Ingelheim: Coming together as one: Working towards a better outcome in oncology
- Industry Satellite: Caris Life Sciences: Evidence based molecular profiling: Putting the theory of personalised medicine into practice
- Industry Satellite: Celgene: Pancreatic cancer: Making an impact through innovation
- Industry Satellite: Celgene: Strategies for selecting therapy in HER2-negative breast cancer
- Industry Satellite: Daiichi: MET: A major target in oncology
- Industry Satellite: Delcath: Chemosaturation therapy: Creating new options in the management of patients with liver dominant disease
- Industry Satellite: Eli Lilly: Orchestrating progress in patients with advanced NSCLC: A symphony of views
- Industry Satellite: GSK: HER2-targeted therapy for metastatic breast cancer: A multidisciplinary approach INVITE
- Industry Satellite: GSK: New evidence, new standards? Redefining treatment selection in mRCC INVITE
- Industry Satellite: Janssen Cilag: Clinical conundrums in the treatment of metastatic castration-resistant prostate cancer
- Industry Satellite: Merck Serono: Beyond chemotherapy: Extending survival for SCCHN patients - a multidisciplinary symposium-
- Industry Satellite: Merck Serono: Maximizing patient benefit in mCRC through personlized care
- Industry Satellite: Novartis: Managing GI malignancies with targeted therapeutics; focus on NET, GIST, and HCC INVITE
- Industry Satellite: Novartis: Targeting advanced breast cancer at the molecular level – translating emerging data into clinical practice INVITE
- Industry Satellite: Novartis: Timely interventions in metastatic RCC: Treatment choices in an intricate landscape INVITE
- Industry Satellite: Pfizer: Right target, right patient, for effective treatment of NSCLC
- Industry Satellite: Pfizer: Targeted therapies in progressive pancreatic NET: Moving from evidence to experience
- Industry Satellite: Pfizer: The evolving paradigm of targeted therapy: Optimising long-term outcomes for patients with mRCC
- Industry Satellite: Roche: Beyond convention: New perspectives in NSCLC INVITE
- Industry Satellite: Roche: Clinical advances in HER2-positive breast cancer: Overcoming challenges with patients in mind INVITE
- Industry Satellite: Roche: Individualized treatment strategies to maximize survival in mCRC INVITE
- Industry Satellite: Roche: Integrating bevacizumab into clinical practice in ovarian cancer INVITE
- Industry Satellite: Roche: Personalizing therapy in metastatic melanoma INVITE
- Industry Satellite: Sanofi: Choosing an optimal fit: Exploring treatments for the patient with metastatic colorectal cancer
- Industry Satellite: Sanofi: Metastatic castration resistant prostate cancer (mCRPC): Back to the reality of treating patients
- Industry Satellite: Skeletal Care: Achieving excellence in the management of cancer-related bone disease: The Skeletal Care Academy charter for patient care
- Industry Satellite: Takeda: Turning today’s challenges in tomorrow’s success INVITE
- Industry Satellite: Teva Europe: Optimizing the management of chemotherapy in patients with breast cancer
- Industry Satellite: prIME Oncology: Complex issues in hormone receptor-negative metastatic breast cancer: Weighing the options
- Industry Satellite: prIME Oncology: Expanding horizons in the therapeutic landscape for relapsed ovarian cancer
- Integrating targeted treatments with tumor biology and molecular imaging in the current and future management of neuroendocrine gastrointestinal tumors
- Intensified locoregional treatment of rectal cancer
- Is aspirin (NSAID) ready for chemoprevention of colorectal adenoma/cancer?
- Issues in adjuvant treatment of common tumors (with a focus on breast cancer) in older adults (age> 70)
- Issues in adjuvant treatment of common tumors (with a focus on breast cancer) in older adults (age> 70)- Repetition
- Issues in sarcoma
- Issues in sarcoma - Repetition
- Issues in the treatment of young women
- Is thromboprophylaxis mandatory in the management of patients with advanced cancer?
- Key topics in supportive care
- Latest advances in breast cancers
- Latest advances in colorectal cancers
- Latest advances in hematological malignances
- Latest advances in lung cancer
- Latest advances in prostate cancers
- Latest innovations in NSCLC management
- Less is not always more: Systemic treatment and surgery of relapsed and refractory testis cancer
- Locally advanced disease: Treatment choice based on risk factors in head and neck cancer
- Locally advanced disease: Treatment choice based on risk factors in head and neck cancer- Repetition
- Management of localized gastric cancer
- Managing the costs of emerging therapies in oncology
- Melanoma
- Melanoma
- Melanoma therapy: From frustration to enthusiasm
- Metabolic pathways supporting tumor progression
- Molecular answers and targets on the horizon for the treatment of GU malignancies
- Molecular neuro-oncology: New avenues in diagnosis and treatment
- Molecular oncology: Strategies to improve outcome in NSCLC
- Molecular oncology: Strategies to improve outcome in NSCLC - Repetition
- Molecular targets in malignant lymphomas: From basic science to clinical practice
- Molecular tools for decision making in breast cancers
- Molecular tools for decision making in breast cancers - Repetition
- N2 positive NSCLC
- NETs and endocrine tumors
- NSCLC, metastatic
- NSCLC, metastatic I
- NSCLC - Immunotherapy, SCLC and Mesothelioma
- NSCLC metastatic, II
- Neoadjuvant treatment for breast cancers
- Neoadjuvant treatment for breast cancers - Repetition
- Opening Ceremony
- Optimizing treatment in luminal breast cancer
- Orphan tumors: An ideal niche for selective targeted therapies
- Patient compliance with drug regimes and global treatment efficacy
- Patient rights and obligations
- Personalized medicine
- Poster presentation I
- Poster presentation II
- Poster presentation III
- Practice-based questions for multimodality management of stage III NSCLC
- Presidential Symposium I
- Presidential Symposium II
- Prevention and handling of acute allergic and infusion reactions in oncology
- Prevention and handling of acute allergic and infusion reactions in oncology - Repetition
- Prevention and treatment of skin toxicity
- Psychosocial issues in cancer care
- Publication Only
- Public health and familial cancer
- Pursuing the NED condition in stage IV colorectal cancer
- Quality of life: Financial implications of cancer to the patient and social protection for patients and survivors
- Re-inventing the medical treatment of advanced prostate cancer
- Reducing the incidence and mortality of major cancer types by drugs? Facts and hopes
- Sarcoma
- Sarcoma
- Screening and early-detection of lung cancer
- Screening and early-detection of lung cancer - Repetition
- Sigmoid cancer and hepatic metastases
- Society Session: BDA. New oncology drugs – Approval process and reimbursement systems in Europe
- Society Session OECI: Do quality programmes make our patients feel better and healthier?
- Society session - ESO - Celebrating 30 years of ESO and 50 issues of Cancer World. Cancer 2020: The road to personalized cancer care
- Stage 1 endometrial cancer
- Subtyping soft tissue sarcomas for treatment approaches
- Supportive and palliative care
- Supportive and palliative care: Controlling disease and treatment side-effects
- Surveillance or adjuvant treatments in stage 1 testis germ cell tumors
- Surveillance or adjuvant treatments in stage 1 testis germ cell tumors - Repetition
- Targeted treatments in thyroid cancer
- Targeted treatments in thyroid cancer - Repetition
- The best of the ESMO 2012 Congress
- The challenges of clinical research: Risk of extinction?
- The characterization of lung cancer in multiple different diseases
- The current management of castrate-resistant prostate cancer (CRPC)
- The current management of castrate-resistant prostate cancer (CRPC) - Repetition
- The hallmarks of cancer revisited
- The handling of toxicity in newly approved melanoma therapies
- The impact of the cancer genome project and high-throughput analyses on personalised oncology: Today and tomorrow
- The retroperitoneal mass: When to use which treatment
- The role of complementary medicine in cancer therapy
- Towards integrated management of patients with carcinoma of an unknown primary site (CUP)
- Towards integrated management of patients with carcinoma of an unknown primary site (CUP)-Repetition
- Treatment, guidelines, standards and quality assurance
- Treatment of trastuzumab and lapatinib resistant patients
- Updates in supportive and palliative care
- Updates in supportive and palliative care - Repetition
- What is the clinical value of isolated tumor cells and micrometastases in sentinel node?
- When to order a biopsy to characterize a metastatic relapse in breast cancer
- When to order a biopsy to characterize a metastatic relapse in breast cancer - Repetition
- When to treat relapsed ovarian cancer
- YO Masterclass: Clinical trial protocol development
- Young Oncologist Vesalius Cocktail - Experience meets youth in career development

